Corvus Pharmaceuticals (CRVS) EBITDA (2015 - 2026)

Corvus Pharmaceuticals' EBITDA history runs 12 years deep, the most recent figure standing at -$13.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 191.43% year-over-year to -$13.9 million; the TTM figure through Mar 2026 stood at -$44.0 million (down 6.43% YoY), while the FY2025 annual figure was -$14.9 million, up 76.22% from the prior year.
• EBITDA was -$13.9 million for Q1 2026 at Corvus Pharmaceuticals, down from -$12.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $15.2 million in Q1 2025 to a low of -$39.6 million in Q3 2024.
• Historically, EBITDA has averaged -$9.6 million across 5 years, with a median of -$8.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA tumbled 551.85% in 2024, then jumped 353.4% in 2025.
• A 5-year view of EBITDA shows it stood at -$9.2 million in 2022, then soared by 32.76% to -$6.2 million in 2023, then sank by 105.0% to -$12.7 million in 2024, then climbed by 4.0% to -$12.2 million in 2025, then declined by 14.52% to -$13.9 million in 2026.
• The last three EBITDA figures came in at -$13.9 million (Q1 2026), -$12.2 million (Q4 2025), and -$10.1 million (Q3 2025), per Business Quant data.